Key result
BF061 prevented thrombus formation similarly to clopidogrel in mouse models of arterial thrombosis, while inducing dramatically less bleeding.
Why the study?
Does BF061 inhibit platelet activation and thrombosis with less bleeding compared to clopidogrel in preclinical models?
Does BF061 inhibit platelet activation and thrombosis with less bleeding compared to clopidogrel in preclinical models?
BF061 is a novel dual-action antiplatelet agent (P2Y12 antagonist and PDE inhibitor) that shows comparable antithrombotic efficacy to clopidogrel with significantly less bleeding in mouse models.
No takes yet. Share an insight, caveat, or question.
May justify first-in-human trials of this dual-action agent; leaves open clinical translation of reduced bleeding.
Hu et al. (2011) studied Thrombosis. BF061 vs. clopidogrel was evaluated on Thrombus formation and bleeding. BF061 prevented thrombus formation similarly to clopidogrel in mouse models of arterial thrombosis, while inducing dramatically less bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: